‘Extreme Outlier’ Vertex Slammed For Orkambi Pricing Approach In England

The national health service in England and the UK health technology assessment body NICE have attacked Vertex Pharmaceuticals Inc. for refusing to budge on the price of its cystic fibrosis drug Orkambi (ivacaftor/lumacaftor) and have criticized the company for instead trying to change the HTA process to secure the revenue that it wants.

The criticism came during a heated public hearing that was held as part of a parliamentary inquiry into the availability of Orkambi – or rather the lack of it – on the NHS in England